Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study - PubMed

Clinical Trial

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

D J Klaassen et al. J Clin Oncol. 1985 Mar.

Abstract

One hundred ninety-one patients with pathologically confirmed, locally unresectable adenocarcinoma of the stomach (57 patients) and pancreas (91 patients), were randomly allocated to therapy with 5-fluorouracil (5-FU) alone, 600 mg/m2 intravenously (IV) once weekly, or radiation therapy, 4,000 rad, plus adjuvant 5-FU, 600 mg/m2 IV, the first three days of radiotherapy, then follow-up maintenance 5-FU, 600 mg/m2, weekly. Forty-three patients (22%) could not be analyzed because of ineligibility or cancellation, thus 148 patients were evaluable. The median survival time was similar for both treatment programs and for both types of primary carcinoma, and was as follows: gastric primary carcinoma, 5-FU, 9.3 months; 5-FU plus radiotherapy, 8.2 months; pancreatic primary carcinoma, 5-FU, 8.2 months; 5-FU plus radiotherapy, 8.3 months. Substantially more toxicity was experienced by patients treated with the combined modality arm than by those patients receiving 5-FU alone. Severe or worse toxicity experienced by patients with gastric primary carcinoma treated by 5-FU was 19%, and the combined modality arm was 31%. The toxicity experienced by patients with pancreatic primary carcinoma treated with 5-FU was 27%, and the combined modality arm was 51%. Significant prognostic variables included: weight loss in stomach-cancer patients; and performance status, degree of anaplasia, and reduced appetite in pancreas-cancer patients.

Similar articles

• Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.

  Keene KS, Rich TA, Penberthy DR, Shepard RC, Adams R, Jones RS. Keene KS, et al. Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):97-103. doi: 10.1016/j.ijrobp.2004.08.053. Int J Radiat Oncol Biol Phys. 2005. PMID: 15850908

• Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

  Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA. Crane CH, et al. Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1293-302. doi: 10.1016/s0360-3016(01)02740-7. Int J Radiat Oncol Biol Phys. 2002. PMID: 11955742

• A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.

  Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG; Eastern Cooperative Oncology Group. Cohen SJ, et al. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50. doi: 10.1016/j.ijrobp.2004.12.074. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029791 Clinical Trial.

• Paclitaxel and concurrent radiation in upper gastrointestinal cancers.

  Constantinou M, Tsai JY, Safran H. Constantinou M, et al. Cancer Invest. 2003;21(6):887-96. doi: 10.1081/cnv-120025092. Cancer Invest. 2003. PMID: 14735693 Review.

• Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies.

  Tepper JE. Tepper JE. Semin Oncol. 1992 Aug;19(4 Suppl 11):96-101. Semin Oncol. 1992. PMID: 1509287 Review.

Cited by

• Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis.

  Cao BY, Zhang LT, Wu CC, Wang J, Yang L. Cao BY, et al. Front Oncol. 2024 Sep 16;14:1473251. doi: 10.3389/fonc.2024.1473251. eCollection 2024. Front Oncol. 2024. PMID: 39359428 Free PMC article.

• Advanced-stage pancreatic cancer: therapy options.

  Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Werner J, et al. Nat Rev Clin Oncol. 2013 Jun;10(6):323-33. doi: 10.1038/nrclinonc.2013.66. Epub 2013 Apr 30. Nat Rev Clin Oncol. 2013. PMID: 23629472 Review.

• Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience.

  Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, Gibbs J, Kuvshinoff B, Wilding G, Warren G, Yang GY. Malik NK, et al. J Gastrointest Oncol. 2012 Dec;3(4):326-34. doi: 10.3978/j.issn.2078-6891.2012.029. J Gastrointest Oncol. 2012. PMID: 23205309 Free PMC article.

• The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

  Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group. Goldstein D, et al. Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1. Br J Cancer. 2012. PMID: 22134511 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information